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Cyclosporine in patients with steroid-resistant membranous Membranous nephropathy (MGN) is the most com-
nephropathy: A randomized trial. mon cause of adult-onset idiopathic nephrotic syndrome.
Background. A clinical trial of cyclosporine in patients with Although the overall renal survival percentage remainssteroid-resistant membranous nephropathy (MGN) was con-
high at 10 years, its incidence rate results in the diseaseducted. Although MGN remains the most common cause of
being the second or third most common primary glomer-adult-onset nephrotic syndrome, its management is still contro-
versial. Cyclosporine has been shown to be effective in cases ulopathy to terminate in end-stage renal failure (ESRF)
of progressive MGN, but it has not been used in controlled [1–3]. The additional morbidity and mortality associated
studies at an early stage of the disease. with the accelerated vascular disease and the propensityMethods. We conducted a randomized trial in 51 biopsy-
for thromboembolic events in patients with persistentproven idiopathic MGN patients with nephrotic-range protein-
high-grade proteinuria are also substantial. The pathol-uria comparing 26 weeks of cyclosporine treatment plus low-
dose prednisone to placebo plus prednisone. All patients were ogy and natural history of the disorder have been clearly
followed for an average of 78 weeks, and the short- and long- defined since its initial description, but specific treat-
term effects on renal function were assessed. ment, tested in randomized controlled trials, has beenResults. Seventy-five percent of the treatment group versus
limited. One routine that has been proven to be effective22% of the control group (P , 0.001) had a partial or complete
in low-risk patients utilizes a combination of a cytotoxicremission of their proteinuria by 26 weeks. Relapse occurred
in 43% (N 5 9) of the cyclosporine remission group and 40% agent alternating with corticosteroids in a cyclical regime
(N 5 2) of the placebo group by week 52. The fraction of the over a six-month period [4, 5]. Ten-year follow-up results
total population in remission then remained almost unchanged with this routine have demonstrated both an improve-and significant different between the groups until the end of
ment in renal survival and in time spent in a non-nephroticthe study (cyclosporine 39%, placebo 13%, P 5 0.007). Renal
state, but its adverse effects, especially in the presencefunction was unchanged and equal in the two groups over
the test medication period. In the subsequent follow-up, renal of renal insufficiency and the relatively high ESRF rate
insufficiency, defined as doubling of baseline creatinine, was in the placebo group compared with other studies [6, 7],
seen in two patients in each group, but remained equal and have provoked intense debate and a reluctance in manystable in all of the other patients.
centers to adopt this approach routinely. CorticosteroidConclusion. This study suggests that cyclosporine is an effec-
therapy alone has also been tried in controlled trials.tive therapeutic agent in the treatment of steroid-resistant cases
of MGN. Although a high relapse does occur, 39% of the The two most recent studies have indicated no significant
treated patients remained in remission and were subnephrotic benefit with this approach [8, 9]. Other agents and rou-
for at least one-year post-treatment, with no adverse effect on tines have been advocated, but the results have been in-filtration function.
consistent, derived from uncontrolled trials and/or in
studies with numbers too small to be meaningful [10–14].
Cyclosporine is a well-known and effective immuno-Key words: immunosuppression, clinical trial, adult onset nephrotic syn-
drome, progressive renal disease, proteinuria, end-stage renal failure. suppressive agent that has been used in most solid organ
transplant programs for the past 15 years. CyclosporineReceived for publication July 7, 2000
has also been used as treatment of MGN for over 10and in revised form September 28, 2000
Accepted for publication October 11, 2000 years, but most studies have been open labeled and non-
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both a short and long-term benefit to this therapy in converting enzyme inhibitor (ACE I) or an angioten-
sin II receptor antagonist from the start of the six-monthMGN patients with renal insufficiency [17]. The num-
bers, however, were small, and the entry criteria were observation period could remain on it, but the introduc-
tion of these classes of drugs was forbidden during thestrict. Also, the trial data would only support its applica-
tion in the small proportion of the MGN population test period. All other antihypertensive agents were al-
lowed. Patients were instructed to follow a diet of 0.8 g/with a clearly documented progressive decline in renal
function. We report the first randomized controlled trial kg/day of protein. Also in most cases, a no added salt
and low cholesterol intake diet was recommended. Eachof cyclosporine in adults with steroid-resistant MGN and
nephrotic-range proteinuria but with preserved renal patient had a minimum of three protocol visits prior to
randomization, with two mandated within the six-weekfunction.
period prior to the start of the test medication.
METHODS Randomization and treatment
A prospective, single-blind, randomized trial was per- A full history and physical evaluation as well as labora-
formed in 11 centers in North America. The study proto- tory tests, including serum creatinine and 24-hour urine
col was reviewed and approved by each center’s institu- collection estimates of protein, creatinine, and urea, were
tional review board, and a signed consent was obtained repeated at the time of randomization. A lipid profile,
from all patients prior to entry. including cholesterol and triglyceride estimation, was also
done. An inclusion/exclusion checklist was maintained
Observation period and entry criteria
centrally and reviewed prior to group assignment. Ran-
The age at entry was between 18 and 70 years. All domization was performed by the clinical coordinating
patients must have failed to achieve remission of their center from a table of random numbers and was stratified
proteinuria after a minimum of eight weeks of predni- by center in blocks of two to ensure a balance between
sone treatment at $1 mg/kg/day. A renal biopsy was groups. The patients were masked in regards to active
required within three years of trial entry, and a local versus placebo assignment, but the physicians were not
pathology review had to confirm by light, immunofluo- for safety reasons and because the end points were objec-
rescent, and electron microscopy all of the classic fea- tive and measured centrally by a lab blinded to patient
tures of MGN [18]. The renal tissue was subsequently designation. Novartis Canada Ltd. (Whitby, Ontario, Can-
reviewed by a nephropathologist masked to patient as- ada) provided cyclosporine in a drink solution (100 mg/mL)
signment who scored each biopsy 0 to 31 in the categories and an identical placebo made from the same carrier.
of interstitial disease (none, mild, moderate, or severe), Treatment was started at a dose of 3.5 mg/kg/day in the
the percentage glomerular sclerosis/obsolescence, and active group and 0.035 mL/kg/day in the placebo group.
the dominant stage of the deposits by electron micros- The daily quantity was divided and given in two equal
copy [1–4]. Exclusion criteria included women unwilling doses at 12-hour intervals. Adjustments in dosages were
to take effective birth control measures, comorbid condi- made in the cyclosporine patients to achieve a whole-blood
tions with an expected survival of less than two years, 12-hour trough level measured by monoclonal assay be-
and any serious systemic infection or associated disorders tween 125 and 225 mg/L. A comparable number of adjust-
requiring daily nonsteroidal anti-inflammatory medica- ments were made in the placebo patient’s medication
tions. Also excluded were patients with diabetes mellitus, volume to ensure that masking was maintained. The
malignancy, and other conditions known to be associated test medications were continued for 26 weeks and then
with secondary MGN such as the drugs phenytoin and tapered to zero over 4 weeks. All study patients received
gold salts, immunologic conditions such as systemic lupus prednisone at 0.15 mg/kg/day up to a maximum dose of
erythematosus (SLE), and infections, including malaria 15 mg. This was reduced after 26 weeks by thirds at 4-week
and hepatitis B and hepatitis C. No immunosuppressive intervals and was stopped after 8 weeks. Renal function
agents, plasma exchange therapy, or antilymphocyte prod- tests were repeated on the day of randomization, and
ucts were allowed in the six months prior to the start of follow-up visits were scheduled for one, two, four, six,
the test medication. The following qualifiers had to be and eight weeks and then at four-week intervals until the
fulfilled for the full six months prior to randomization: (1) end of the test medication period. Cyclosporine trough
proteinuria $3.5 g/day or $50 mg/kg, (2) a creatinine levels were also obtained at these intervals. Compliance
clearance $42 mL/min/1.73 m2, and (3) blood pressure was determined by the consistency of the cyclosporine
#135/85 mm Hg. level and by a monthly check of the total volume con-
A seated blood pressure of #135 mm Hg systolic and sumed of the test medication. Visits were then scheduled
#85 mm Hg diastolic was targeted as the upper limit of at eight-week intervals until a study end point was
accepted values before additional treatment during the reached or data closure (December 31, 1998). The pa-
tient was censored if specific immunosuppressive drugsstudy. Any patient who was on either an angiotensin-
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Table 1. Baseline demographic and laboratory data of theor corticosteroids were started after the test medication
51 randomized patients
period. The patients’ clinical status and vital signs were
Placebo Cyclosporinerecorded, and electrolytes, hematology, and renal and
Initial N 5 23 N 5 28
liver function tests were monitored at each visit. Serum
Age range 49614 47611creatinine and 24-hour urine excretion rates of creati- Gender M/F 16/7 26/2
Blood pressure mm Hgnine, protein, and urea were measured by a central lab
Systolic 138616 137618using standard methods.
Diastolic 8469 8467
Racial group N (%)
Caucasians 20 (87) 24 (86)Outcome measures
African American 0 (0) 1 (4)
The primary outcome was the number of complete Other/Mixed 3 (13) 2 (10)
Serum albumin g/dL 2.760.6 2.860.6(CR) or partial remissions (PRs) in proteinuria at week
Serum creatinine mg/dLa 1.160.3 1.360.526. This was also assessed at weeks 52 and 78. CR was Creatinine clearance mL/min/1.73 m2 95637 90627
defined as #0.3 g/day proteinuria plus stable renal func- Proteinuria g/day 8.864.7 9.765.3
Urine urea g/day 9.563.6 10.364.0tion, PR as a 50% reduction of initial proteinuria, and
Data that are 6 values are standard deviations.less than 3.5 g/day with stable renal function. Stable
a To convert to mmol/L, multiply by 88.4
function was defined as a creatinine clearance estimate
within 15% of the baseline value obtained in each patient
at the time of randomization. Secondary analyses in-
RESULTScluded time to a 50% reduction in baseline creatinine
Fifty-seven patients were screened and deemed eligi-clearance and to doubling of baseline creatinine. Study
ble by the local principle investigator, and they signedend points were week 78, end-stage renal disease defined
a consent form. Review subsequently eliminated six pa-as a creatinine clearance of less than 12 mL/min, start
tients prior to randomization because of a failure toof dialysis or transplantation or study closure date. Early
confirm the histologic diagnosis (N 5 1), central mea-stop points included a confirmed $30% rise in baseline
surement of proteinuria ,3.5 g/day (N 5 2), creatinineserum creatinine. Confirmed meant that the creatinine
clearance ,42 mL/min (N 5 2), and the diagnosis ofwas not improved by two 25% reductions in the dose of
a malignancy during the six-month observation periodthe test medication spaced out over a four-week period.
(N 5 1).Other premature stop points included doubling of base-
The average per patient prednisone dose given prior
line liver enzymes and intolerable side effects. The test to the six-month run-in period was not different in the
medication was also stopped if a CR of proteinuria was two groups. In the placebo group, the mean total dose
achieved and persisted for one month or more. was 92 mg/kg (range 65 to 120), and in the cyclosporine
group, it was 108 mg/kg (range 60 to 140). The mean
Data analysis duration of treatment was also similar at 12 weeks in
A prospective construction of sample size based on the placebo patients (range 8 to 22) and 14 weeks in the
cyclosporine patients (range 8 to 28). In addition, in theanalysis of two independent proportions using an a of
pretrial period, 18 patients (10 placebo and 8 cyclo-0.05 and a b of 0.2 and a difference in remission rates in
sporine) had failed a course of a cytotoxic agents (9proteinuria at 26 weeks of 30% plus an estimated drop-
cyclophosphamide, 5 chlorambucil, 4 azathioprine) forout rate of 10% indicated that 25 patients per arm were
an average of four months (range 2 to 12).needed. Results were analysis by chi square for pro-
There were no significant differences in any of theportions and, if appropriate, the nonparametric Mann–
demographic or laboratory feature at baseline betweenWhitney rank sum test. The length of time to event
the two groups (Table 1). Overall, the racial group wasanalysis utilized Kaplan–Meier product-limit life-table
predominately Caucasian, and the ratio of male to femalesurvival estimate compared by the log rank test. All tests
was dominated by males at approximately 5:1. The urine
were two sided and analyzed on the basis of all patients urea, a reflection of dietary protein intake, was equal in
maintained in their original assigned group. Differences both groups. The central pathology review revealed no
in renal function over time were compared by t-test of difference between the cyclosporine and the placebo
the slopes of creatinine clearance and reciprocal of creat- group’s average score in regards to either stage [2.2
inine over the 26 weeks of the test medication and over (range 1 to 4) vs. 2.4 (range 1 to 4)] or interstitial scarring
the total observation period. Values in the tables are [0.6 range (0 to 2) vs. 0.6 range (0 to 3)]. Global and/or
means 6 SD unless otherwise stated. The analyses were segmental sclerosis was equal and seen in 32% of
performed with the Statistical Analysis System (version cyclosporine patients (8 to 33% of glomeruli) versus 30%
of placebo patients (5 to 24% of glomeruli). Effects of6.12) software [19].
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The mean cyclosporine dose was 3.7 mg/kg (62.0).
The mean trough level in the cyclosporine group at 26
weeks was 148 6 29 ng/L. All patients completed the
six months of the test medications except one case of
CR, where the cyclosporine was stopped at week 20 after
4 weeks with no proteinuria. An increase in baseline
creatinine of 30% occurred in 12 patients (9 cyclosporine
and 3 placebo). In seven cases on cyclosporine, the creati-
nine returned to baseline with dose reduction. The other
two progressed slowly to renal failure despite stopping
the cyclosporine. In the placebo group with dose reduc-
tion, one returned to baseline, and two continued to
renal failure. Compliance as judged by both the monthly
consumption of the test medication and by the troughFig. 1. Remissions in proteinuria in the cyclosporine patients [( )
partial, (j) complete] compared with the placebo-treated [( ) com- level consistency indicated adherence to the prescribed
plete, (h) partial] at different time points of the study. At week 26, regime in .90% in all patients.P 5 0.001; at week 52, P 5 0.004; and week 78, P 5 0.007. Early stops
At randomization, 53% (N 5 27) of the patients were(*) were assessed at the last follow-up.
hypertensive (16 cyclosporine and 11 placebo). Nineteen
were on ACE I (11 cyclosporine 8 placebo), and eight
were on other antihypertensive medications. During the
the test medication on remission rates over time are cyclosporine period, there was an increase in the number
illustrated in Figures 1 and 2. Remission occurred in of patients in both groups that required antihypertensive
75% (21 out of 28) of the cyclosporine group versus 22% medication, but more in the cyclosporine than in the
(5 out of 23) of the placebo group by 26 weeks (P , placebo group (8 vs. 5). Despite this, no significant differ-
0.001). Time to CR ranged from 16 to 26 weeks and to ences in supine, sitting, or mean arterial pressure mea-
PR from 2 to 26 weeks with a mean of 14. One patient surements were noted during the active medication pe-
in CR in the cyclosporine group did not relapse in up riod or during the post-cyclosporine period (Fig. 3).
to 200 weeks of follow-up, and one relapsed to PR at However, since ACE I could not be introduced in this
week 53. Two PRs went onto CR in the cyclosporine period, these additional cases resulted in a decreased
group, one at week 70 and one at week 200. Ten of the percentage of the hypertensive patients within each
PRs in the cyclosporine group relapsed between 28 and group on this class of cyclosporine. In the cyclosporine
70 weeks (mean of 39). In the placebo group, the CR group, this fell from 69 to 46% and in the placebo group
during treatment relapsed at week 64. However, a differ- from 73 to 50%. During the post-test medication period,
ent placebo patient went on to CR at week 66. In the neither the percentage of patients with hypertension nor
four PRs, two relapsed, one at week 32 and one at week the use of ACE I changed significantly. There was no
48. The overall percentage in remission remained sig- difference in the cyclosporine group between those on
nificantly between different groups at week 78 or the ACE I compared with those not on an ACE inhibitors
last observation point in the four patients who had an in either baseline proteinuria or in the amount of protein
early stop point [cyclosporine 39% (11 out of 28), pla- reduction by week 26.
cebo 13% (3 out of 23), P 5 0.007]. Dietary compliance over the study period, as moni-
Renal failure assessed by log rank test using a 50% tored by monthly urine urea, indicated good adherence
reduction in baseline creatinine clearance as an end point with the mean in mmol/day in the placebo group and no
was seen in 9% (N 5 2) of the placebo group (at weeks difference from the cyclosporine group at weeks 26 (10
42 and 64) and 7% (N 5 2) of the cyclosporine group vs. 11.6), 52 (9.8 vs. 10.7), and 78 (9.9 vs. 10.6). In the
(at weeks 42 and 78) by 78 weeks (P 5 NS). The slope 420 urine urea assessments, only 40 values indicated a
of creatinine clearance in mL/min/month was also similar dietary protein intake of .20% above the recommended
in the two groups at the end of six months of active value. The majority of these were seen in four patients
treatment (placebo 24 6 9, medium 22.5 vs. cyclospor- (2 placebo and 2 cyclosporine).
ine 24 6 10, medium 21.9) and over the total observa-
Adverse effectstion time (placebo 21.1 6 2.4, medium 20.5 vs. cyclo-
sporine 20.3 6 1.2, medium 20.04; P 5 0.2). There were The number as well as the severity of hypertension was
four patients who did not complete the full 78 weeks of greater in the cyclosporine compared with the placebo
follow-up. The reasons were ESRF (N 5 1), relocation group in the active treatment period. A new antihyper-
outside of North America (N 5 1), noncompliance (N 5 tensive agent (N 5 8) or an increase in the dose of
the antihypertensive drugs (N 5 2) was required in the1), and a death due to postmyocardial infarction (N 5 1).
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Fig. 2. Remission and relapses in the two
groups over the study and follow-up period.
Abbreviations are: CR, complete remission;
PR, partial remission; NR, no remission; R,
relapse.
worse prognosis have included age, male gender, hyper-
tension, and degree of glomerulosclerosis on biopsy
[24–26]. Some studies have suggested that steroid resis-
tance is an independent risk factor [27]. We have pre-
viously described and validated a semiquantitative
method of predicting outcome [28, 29]. In its simplest
form, it demonstrated an improved accuracy of pre-
dicting outcome by utilizing the persistence of protein-
uria above certain levels over six months of observation.
If the initial proteinuria, for example, is .3.5 g/day, the
overall prediction accuracy is 50%, but if it remains at
this level for six months, this improves to 75%. The
presence of persistent high-grade proteinuria has alsoFig. 3. Mean sitting systolic and diastolic pressures at the end of each
time period by the (d) cyclosporine and (s) placebo groups. The been documented in a number of other primary nephrop-
whiskers represent the standard deviations. P 5 NS at all points. athies to indicate a poor prognosis [30, 31]. In order for
us to select at an early stage a population with a signifi-
cant risk of progression, we applied these entry criteria
in our trial.cyclosporine group versus a new agent (N 5 5) in the
In a recent, year-long, randomized trial of cyclosporineplacebo group. The only other sign or symptom of toxic-
in MGN patients that had a documented a decline inity was mild nausea in five patients, four on cyclosporine
glomerular filtration rare, we showed both a substantialand one on placebo. This resolved spontaneously in all
reduction in proteinuria and a slowing in the rate ofcases by week 8. All 51 patients were maintained on the
deterioration [17]. The study, however, was small, andprescribed prednisone dose for the 26 weeks without any
the cyclosporine was not effective in all patients.noted adverse effects.
Cyclosporine has been used in uncontrolled studies in
MGN, and most have indicated a benefit but associated
DISCUSSION with a significant relapse rate [15, 16, 32, 33]. We wanted
to study its efficacy in a more general but still moderateMembranous nephropathy was defined as a distinct
risk of progression MGN population given that thehistologic variant with the introduction of routine immu-
cyclosporine is expensive and has nephrotoxic potential.nofluorescent and electron microscopy. The natural his-
In our study, proteinuria was substantially reduced intory of untreated ideopathic MGN has been documented
75% of patients compared with 22% of the placeboin several studies. Spontaneous remission has been noted
group. Fifty percent of the remissions did relapse by 78in 20 to 30% of cases and progressive renal failure in
weeks (cyclosporine 48%, N 5 10, placebo 60%, N 5 3).another 20 to 40%, and the remaining patients maintain
However, there was still a statistical and clinically sig-their proteinuria even after 5 to 10 years of observation
[20–23]. Risk factors that have been associated with a nificant difference in those in remission in the cyclo-
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sporine versus the placebo group after the year of follow- were not part of this clinical trial. There was no evidence
that this therapy was associated with improved long-up (39% cyclosporine vs. 13% placebo, P 5 0.007). The
relapse rate was higher than in our earlier year-long term preservation of renal function, but since both dura-
tion and severity of proteinuria are known to be surro-treatment of patients with progressive MGN. This may
be related to the shorter duration of treatment. This is gate markers for progression, it is likely with a longer
observation period that cyclosporine treatment would besupported by uncontrolled but prospective observational
data from the German group that found the mean time associated with improved renal survival similar to our ear-
lier trial [17]. The expected reduction of comorbid con-to response in these MGN patients was in the range of
eight months [16]. Another possibility is that the dose ditions associated with persistent non-nephrotic range
proteinuria would be an additional benefit. These resultsin mg/kg was too low. Although it was similar to our
other MGN trials (3.8 mg/kg), it was marginally lower suggest that this treatment is rational and an important
option in the management of patients with MGN andthan in our recently reported study in patients with focal
segmental glomerulosclerosis (4.2 mg/kg) [34]. Part of persistent high-grade proteinuria.
the reluctance to increase the dose was because of its
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